JP2018521635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521635A5 JP2018521635A5 JP2017561777A JP2017561777A JP2018521635A5 JP 2018521635 A5 JP2018521635 A5 JP 2018521635A5 JP 2017561777 A JP2017561777 A JP 2017561777A JP 2017561777 A JP2017561777 A JP 2017561777A JP 2018521635 A5 JP2018521635 A5 JP 2018521635A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- population
- promoter
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167761P | 2015-05-28 | 2015-05-28 | |
| US62/167,761 | 2015-05-28 | ||
| PCT/US2016/034868 WO2016191750A1 (en) | 2015-05-28 | 2016-05-27 | Cell-based assay for detecting anti-cd3 homodimers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521635A JP2018521635A (ja) | 2018-08-09 |
| JP2018521635A5 true JP2018521635A5 (enExample) | 2019-06-27 |
| JP6810058B2 JP6810058B2 (ja) | 2021-01-06 |
Family
ID=56236065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561777A Active JP6810058B2 (ja) | 2015-05-28 | 2016-05-27 | 抗ｃｄ３ホモ二量体を検出するための細胞に基づくアッセイ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10690678B2 (enExample) |
| EP (2) | EP3795679A1 (enExample) |
| JP (1) | JP6810058B2 (enExample) |
| KR (1) | KR102583058B1 (enExample) |
| CN (1) | CN107646038B (enExample) |
| AU (1) | AU2016267691B2 (enExample) |
| CA (1) | CA2987403A1 (enExample) |
| ES (1) | ES2823033T3 (enExample) |
| HR (1) | HRP20201779T1 (enExample) |
| IL (1) | IL255696B (enExample) |
| MX (1) | MX392706B (enExample) |
| SG (1) | SG10201911335TA (enExample) |
| SI (1) | SI3303400T1 (enExample) |
| WO (1) | WO2016191750A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| CN109073635A (zh) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于测定t细胞依赖性双特异性抗体的方法 |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| WO2018108759A1 (en) * | 2016-12-13 | 2018-06-21 | F. Hoffmann-La Roche Ag | Method to determine the presence of a target antigen in a tumor sample |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| CN108918892B (zh) * | 2018-08-01 | 2021-04-27 | 百奥泰生物制药股份有限公司 | 一种测定抗vegf抗体活性的方法及其应用 |
| TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CN111077311B (zh) * | 2019-12-30 | 2023-05-09 | 北京立康生命科技有限公司 | 一种酶联免疫斑点检测试剂盒及其检测方法 |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| CN112458149B (zh) * | 2020-12-03 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法 |
| CN112921004B (zh) * | 2021-02-05 | 2023-08-08 | 上海精翰生物科技有限公司 | 用于cd3受体激动剂检测的细胞株及其构建方法及cd3受体激动剂检测方法 |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2023250485A1 (en) | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CN109073635A (zh) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于测定t细胞依赖性双特异性抗体的方法 |
-
2016
- 2016-05-27 HR HRP20201779TT patent/HRP20201779T1/hr unknown
- 2016-05-27 JP JP2017561777A patent/JP6810058B2/ja active Active
- 2016-05-27 EP EP20190490.1A patent/EP3795679A1/en not_active Withdrawn
- 2016-05-27 ES ES16732377T patent/ES2823033T3/es active Active
- 2016-05-27 CA CA2987403A patent/CA2987403A1/en active Pending
- 2016-05-27 AU AU2016267691A patent/AU2016267691B2/en active Active
- 2016-05-27 SG SG10201911335TA patent/SG10201911335TA/en unknown
- 2016-05-27 EP EP16732377.3A patent/EP3303400B1/en active Active
- 2016-05-27 SI SI201631004T patent/SI3303400T1/sl unknown
- 2016-05-27 MX MX2017015011A patent/MX392706B/es unknown
- 2016-05-27 KR KR1020177036974A patent/KR102583058B1/ko active Active
- 2016-05-27 CN CN201680030308.8A patent/CN107646038B/zh active Active
- 2016-05-27 WO PCT/US2016/034868 patent/WO2016191750A1/en not_active Ceased
-
2017
- 2017-11-15 IL IL255696A patent/IL255696B/en unknown
- 2017-11-28 US US15/824,992 patent/US10690678B2/en active Active
-
2020
- 2020-05-14 US US16/874,550 patent/US12007398B2/en active Active
-
2024
- 2024-04-16 US US18/636,947 patent/US20240280586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521635A5 (enExample) | ||
| HRP20201779T1 (hr) | Stanični test za otkrivanje anti-cd3 homodimera | |
| JP2019504321A5 (enExample) | ||
| Ramesh et al. | A palette of cytokines to measure anti-tumor efficacy of T cell-based therapeutics | |
| EP3404410A3 (en) | Biosensor system for the rapid detection of analytes | |
| Lytton et al. | Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins | |
| EP2663857A2 (en) | Protein detection method | |
| WO2012075506A3 (en) | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses | |
| BR112015022844A8 (pt) | método para determinar a presença ou ausência de anticorpos específicos do doador em uma amostra biológica, sistema e kit para praticar o mesmo | |
| JP2016512044A5 (enExample) | ||
| MX2014010068A (es) | Metodos y sistemas para amplificacion de señal de bioensayos. | |
| Kuuliala et al. | Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis | |
| Pantelyushin et al. | Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs | |
| HRP20211418T1 (hr) | Čestice polimera i njihova uporaba | |
| Goyal et al. | Estimation of lymphocyte subsets and cytokine levels in workers occupationally exposed to cadmium | |
| Yoo et al. | Co-autodisplay of Z-domains and bovine caseins on the outer membrane of E. coli | |
| Hillen et al. | Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis | |
| WO2007037910A3 (en) | Specific removal of activated immune cells | |
| EP4253950A3 (en) | Ce-western applications for antibody development | |
| Valera et al. | Application of bioassays/biosensors for the analysis of pharmaceuticals in environmental samples | |
| Oth et al. | Monitoring the initiation and kinetics of human dendritic cell-induced polarization of autologous naive CD4+ T cells | |
| WO2013155605A8 (en) | Method for predicting a pathophysiological condition in an animal | |
| JP2015507200A5 (enExample) | ||
| Clutter et al. | 131 Combining high-plex proteomics with single-cell transcriptomics for deep characterization of antigen-specific T cell responses | |
| Luo et al. | Lateral Flow Immunoassay for Rapid and Sensitive |